SOUTH SAN FRANCISCO, Calif. , June 02, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the Goldman Sachs 42 nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 12:50 pm PT / 3:50 pm ET . Gerrit Klaerner , Tricida’s Founder, President

Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO , May 06, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, May 6th by Tricida, Inc. (Nasdaq: TCDA), please note that the first and second bullets of the "Upcoming Milestones" should have been combined into

Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO , May 06, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed

SOUTH SAN FRANCISCO, Calif. , April 27, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its first quarter 2021 financial results after the close of market on Thursday, May 6, 2021 . Tricida will host a conference call and webcast at 4:30 pm Eastern Time to

SOUTH SAN FRANCISCO, Calif. , April 08, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 20 th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 12:45 pm PT / 3:45 pm ET . Tricida will provide a company overview, business

SOUTH SAN FRANCISCO, Calif. , April 05, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis

Extends Veverimer Patent Protection into 2038 SOUTH SAN FRANCISCO, Calif. , March 03, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed,

SOUTH SAN FRANCISCO, Calif. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic

Tricida Has Received an Appeal Denied Letter from the Office of New Drugs of the FDA in Response to its Formal Dispute Resolution Request SOUTH SAN FRANCISCO, Calif. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and

SOUTH SAN FRANCISCO, Calif. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its fourth quarter and year-end 2020 financial results after the close of market on Thursday, February 25, 2021 . Tricida will host a conference call and webcast at 4:30